GLOW (GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously. This schedule maintains a consistent dose throughout the 4-week cycle, delivering approximately 1.7 mg GHK-Cu, 0.33 mg TB-500, and 0.33 mg BPC-157 per injection. For 10 unit (0.10 mL) or smaller administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall to minimize foaming.
3. Gently swirl or roll the vial until fully dissolved (do not shake vigorously).
4. Label with reconstitution date and refrigerate at 2 to 8 °C, protected from light.
5. Use within 4 weeks for optimal potency and safety. At 23.3 mg/mL, 1 unit = 0.01 mL » 233 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C or below for long-term stability (months to over a year). If freezer unavailable,

refrigeration at 2 to 8 °C is acceptable for shorter durations.

• Reconstituted: refrigerate at 2 to 8 °C at all times when not in use; do not freeze reconstituted solution;

use within 4 weeks (28 days).

• Allow frozen vials to reach room temperature before opening to prevent condensation.
• Protect reconstituted solution from light; inspect before each use and discard if discolored, cloudy, or

contains precipitate.

Supplies Needed

Plan based on a 4-week daily protocol at standard dosing.

Peptide Vials (GLOW Blend, 70 mg each):

• 4 weeks (28 days): 1 vial.

Insulin Syringes (U-100, preferably 0.3 mL / 30-unit for precision):

• 4 weeks: 28 syringes (1 per day).

Bacteriostatic Water (10 mL bottles):

• 4 weeks (1 vial): 1 bottle.

Alcohol Swabs:

• 4 weeks: 56 swabs (2 per day, 1 x 100-count box).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container immediately after use.
• Rotate injection sites systematically (abdomen, thighs, upper arms) at least 1 to 2 inches apart.
• Inject slowly over 2 to 3 seconds and wait a few seconds before withdrawing the needle.
• Document daily dose, injection site, and any observations to maintain consistency and track progress.
• Practice aseptic technique at every injection: clean vial stopper and skin with separate alcohol swabs,

allow to air-dry completely.

How This Works

The three peptides in GLOW operate via distinct but complementary biological pathways. GHK-Cu acts as a genomic modulator that can upregulate genes related to tissue growth and downregulate those linked to inflammation and tissue breakdown. It stimulates collagen and glycosaminoglycan synthesis in fibroblasts, promotes angiogenesis, and exhibits antioxidant and anti-inflammatory properties. TB-500 (Thymosin b4) primarily facilitates cell migration and cytoskeletal remodeling by binding to actin and promoting the mobilization of cells to injury sites, accelerating angiogenesis and recruiting stem and progenitor cells. BPC-157 triggers a multi-factorial healing response: it enhances growth factor signaling (VEGF, PDGF), upregulates nitric oxide pathways for improved microcirculation, counteracts inflammatory mediators, and promotes the migration and survival of repair cells. By combining these mechanisms, GLOW supports collagen synthesis, cell migration, angiogenesis, and inflammation control in a single protocol.

Benefits & Side Effects

Observations from preclinical and clinical literature on the component peptides.

• Accelerated wound healing: Thymosin b4 improved closure rate of chronic skin wounds in clinical trials

and animal models; BPC-157 has shown enhanced healing in tendon, muscle, bone, and gut injuries;

GHK-Cu aids wound contraction and epithelialization.

• Anti-inflammatory and pain reduction: All three components mitigate inflammation at injury sites

through complementary pathways.

• Improved tissue quality and reduced fibrosis: TB-500 minimizes fibrous scar tissue; BPC-157

supports organized collagen deposition; GHK-Cu boosts proper collagen and extracellular matrix

production.

• Multi-tissue regeneration: Applicable to orthopedic injuries, dermatologic uses, and potentially

gastrointestinal repair.

• Tolerability: Generally well tolerated; occasional mild injection-site reactions (redness, itching) may

occur.

• Note: large-scale human clinical trials are still needed to confirm efficacy and safety for specific

indications.

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain adequate protein intake (1.6 to 2.2 g/kg body weight daily) to support collagen synthesis and

tissue repair.

• Implement progressive resistance training and appropriate activity modification based on healing goals.
• Prioritize sleep quality (7 to 9 hours nightly) as the primary recovery window for tissue regeneration.
• Manage stress through evidence-based techniques to support an optimal healing hormonal environment.
• Stay well-hydrated and ensure adequate micronutrient intake, particularly vitamin C, zinc, and copper.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Pickart L. Regenerative and Protective Actions of the GHK-Cu Peptide in Light of New Gene Data (Int J Mol Sci, 2018).
2. Thymosin b4 Promotes Dermal Healing (Vitamins & Hormones, 2016).
3. Thymosin b4: A Multi-Functional Regenerative Peptide (Expert Opinion on Biological Therapy, 2012).
4. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (HSS Journal, 2025).